Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Evonik establishes new enzymatic process for serine

17.10.2013
• Evonik Industries has developed a new process for the enzymatic synthesis of the amino acid D-serine, L-serine und DL-serine
• Production capacities at the Nanning site (China) have been increased
• Full backward integration offers customers the highest level of supply security and product quality

Evonik Industries has developed a new, more efficient process for the enzymatic synthesis of the amino acid serine—it is, among other things, required for the production of pharmaceutical ingredients.

To implement the new enzymatic synthesis on a large scale, the Group has expanded the existing production plants at its Nanning site in China. This new process allows Evonik to manufacture serine in all enantiomeric forms: L-serine, D-serine, and DL-serine.

“With the expansion of the production capacities in Nanning we can produce serine in all forms while being fully backward integrated,” says Dr. Jean-Luc Herbeaux, Head of the Health Care Business Line of Evonik. “

“By controlling the entire supply chain, we areclearly a highly reliable partner for our customers—both with regard to supply security and product quality.”

Dr. Thomas Hermann, Vice President of the Rexim Product Line adds: “Because of our technological expertise, we are able to offer all serine-derivatives currently on the market. This gives Evonik a unique value proposition in the market.”

L-serine is one of the non-essential amino acids that are naturally occuring in the human body. It plays an important role in protein synthesis. The main areas of application of L-serine are nutrition and pharmaceutics, but it is also used in the cosmetics industry. In the area of nutrition, amino acids are, for example, used in hypoallergenic follow-on milk for newborns with lactose intolerance, or sports nutrition. L-serine is used in pharmaceutics as a building block for pharmaceutical ingredients or in parenteral nutrition. In the cosmetics sector it is mainly used in skin and hair care products. D-serine and DL-serine are used for the synthesis of various pharmaceutical ingredients.

Evonik offers serine in all quality grades: from technical quality for chiral synthesis to GMP-quality for pharmaceutical applications.

Company information
Evonik, the creative industrial group from Germany, is one of the world leaders

in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Dr. Jürgen Krauter | idw
Further information:
http://www.evonik.com

More articles from Life Sciences:

nachricht Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University

nachricht How herpesviruses win the footrace against the immune system
26.05.2017 | Helmholtz-Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>